Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-3329
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series ; volume:6 ; number:1 ; day:1 ; month:11 ; year:2016 ; pages:1-6 ; date:12.2016
Clinical Sarcoma Research ; 6, Heft 1 (1.11.2016), 1-6, 12.2016
- Creator
-
Lipplaa, Astrid
- Contributor
-
Dijkstra, Sander
Gelderblom, Hans
SpringerLink (Online service)
- DOI
-
10.1186/s13569-016-0059-x
- URN
-
urn:nbn:de:1111-2016112420307
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lipplaa, Astrid
- Dijkstra, Sander
- Gelderblom, Hans
- SpringerLink (Online service)
Other Objects (12)
Einfluss der Tyrosinkinase-Inhibitoren Sorafenib, Sunitinib und Pazopanib auf die zelluläre Aktivität von Nierenkarzinom-Zellen
Pharmacometric approaches for linking pharmacokinetic and pharmacodynamic models of sunitinib and pazopanib with clinical outcome
Reversible Hypopigmentation with Pazopanib
Sunitinib-Sorafenib- versus Sunitinib-Everolimus-Sequenztherapie beim Nierenzellkarzinom
Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis
Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis
Phototoxic Reaction Induced by Pazopanib
Pazopanib and Statin-Induced Rhabdomyolysis
Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis
Pazopanib in advanced soft tissue sarcomas
Einfluss der Tyrosinkinase-Inhibitoren Sorafenib, Sunitinib und Pazopanib auf die zelluläre Aktivität von Nierenkarzinom-Zellen
Pharmacometric approaches for linking pharmacokinetic and pharmacodynamic models of sunitinib and pazopanib with clinical outcome
Reversible Hypopigmentation with Pazopanib
Sunitinib-Sorafenib- versus Sunitinib-Everolimus-Sequenztherapie beim Nierenzellkarzinom
Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis
Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis
Phototoxic Reaction Induced by Pazopanib
Pazopanib and Statin-Induced Rhabdomyolysis
Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis
Pazopanib in advanced soft tissue sarcomas
Einfluss der Tyrosinkinase-Inhibitoren Sorafenib, Sunitinib und Pazopanib auf die zelluläre Aktivität von Nierenkarzinom-Zellen
Pharmacometric approaches for linking pharmacokinetic and pharmacodynamic models of sunitinib and pazopanib with clinical outcome
Reversible Hypopigmentation with Pazopanib
Sunitinib-Sorafenib- versus Sunitinib-Everolimus-Sequenztherapie beim Nierenzellkarzinom
Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis
Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis
Phototoxic Reaction Induced by Pazopanib
Pazopanib and Statin-Induced Rhabdomyolysis
Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis